Long-term study of people with ATTR amyloidosis in routine care
Follows people with ATTR amyloidosis, including treatment with patisiran or vutrisiran.
Plain-language title generated from the registry record
Registry title: ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
Key facts
- Where
- Austin, Baltimore, Boston, Columbus, Durham, Houston, Iowa City, Jacksonville, Kansas City, La Jolla, Los Angeles, New York, and Philadelphia, United StatesSee the 13 sites
Where in United States
- AustinAustin, United StatesTaking people
- BaltimoreBaltimore, United StatesTaking people
- BostonBoston, United StatesNo longer taking part
- ColumbusColumbus, United StatesTaking people
- DurhamDurham, United StatesTaking people
- HoustonHouston, United StatesTaking people
- Iowa CityIowa City, United StatesTaking people
- JacksonvilleJacksonville, United StatesTaking people
- Kansas CityKansas City, United StatesTaking people
- La JollaLa Jolla, United StatesTaking people
- Los AngelesLos Angeles, United StatesTaking people
- New YorkNew York, United StatesTaking people
- PhiladelphiaPhiladelphia, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Alnylam Pharmaceuticals
- Trial code
- NCT04561518
- Record updated
- 13 October 2026
- Original description
The purpose of this study is to:Read full original descriptionShow less
ConTTRibute: A Global Observational Multicenter Long-Term Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
The purpose of this study is to:
* Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients * Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting * Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant
Inclusion: Diagnosis of ATTR amyloidosis or documented known disease-causing TTR variant for the cohort of pre-symptomatic carriers; Germany Only: Patients must be treated per the summary of product characteristics (SmPC) for any approved treatment for ATTR amyloidosis.
Exclusion: Current enrollment in a clinical trial for any investigational agent.